Skip to main content
OpenTrials
Completed

NCT Number: NCT03046576

Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

Increased plasma DPP4 activity (DPP4a) could predict both subclinical and new-onset atherosclerosis, and our previous study has found that the DPP4a was significantly lower in MI patients compared with patients having chest pain or unstable angina alone, and DPP4a is associated with no-reflow and major bleeding events in STEMI patients during hospital stay. As no-reflow phenomenon and major bleeding events independently associates with a worse in-hospital and long-term prognosis. One may speculate that the DPP4a is associated with long-term follow-up adverse cardiovascular events in these patients.The hypothesis was tested in this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Angiography Dipeptidyl Peptidase 4

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • consecutive patients of acute STEMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion criteria

  • patients with cancer, and patients who were taking a DPP4 inhibitoror a glucagon-like peptide-1 (GLP-1) analogue

Treatment and study plan

plasma DPP4 activity

Diagnostic Test

DPP4a was determined by enzymatic assays.

Primary outcomes

  1. major adverse cardiac or cerebrovascular events

    Time frame: The median follow-up was 30 months

    including cardiovascular death, non-fatal myocardial infarction, heart failure and stroke

Secondary outcomes

  1. non-cardiovascular death

    Time frame: The median follow-up was 30 months

  2. repeated revascularization

    Time frame: The median follow-up was 30 months

    defined as repeated PCI or bypass grafting of not only infarct related artery but also non-infarct related artery, driven by ischemic symptoms (stable/unstable angina or re-infarction) or detection of ischemia by non-invasive tests

  3. stroke

    Time frame: The median follow-up was 30 months

    defined using the World Health Organization criteria

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

The Association Between Plasma DPP4 Activity And Prognosis of Patients With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Feb 8, 2017
Registry last updated
Jul 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.